June 20, 2025

Multiple Biological Drivers Identified in Hair Graying

New research identifies oxidative stress, DNA damage, genetic variants, and stem cell depletion as key drivers of hair graying, with emerging therapies under investigation.

Conexiant

June 04, 2025

Past Acne Tied to JAKi Treatment Breakouts: Study

A new study found that patients with a prior history of acne were significantly more likely to develop acne after starting treatment with JAK inhibitors for alopecia areata, especially younger individuals.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant

September 17, 2024

Can Hair Dye Cause Retinopathy?

Aromatic amines may cause long-term RPE dysfunction

Conexiant

July 31, 2024

Alopecia Areata Linked to Mental, Autoimmune Risks

New study published in JAMA Dermatology reveals that patients newly diagnosed with alopecia areata face a higher risk of developing psychiatric and autoimmune disorders.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

November 26, 2024

Do Cancer Drugs Trigger Skin Issues?

A recent analysis reveals that nearly 50% of significant dermatologic adverse events linked to anticancer therapies are associated with targeted therapies, with rash, dry skin, and alopecia being the most commonly reported adverse events.

Conexiant